Table 1

Clinical features, 1-year progression-free survival rate and 1/2-year survival rate for each patient cohort expressing the most frequent alleles in class I human leukocyte antigen (HLA) A, B and C and DRB1

HLA alleleNum (%)Sex:
male/ female
Histology: squamous/non-squamousIrAEs frequencyOne-year progression-free survival rateTwo-year survival rate
A*0239 (41.4%)33/612/27(19) 48.7%57.6%47.7%
A*0128 (29.8%)24/410/18(12) 42.8%74.6%55.9%
B*1825 (26.5%)23/211/14(8) 32.0%50.0%46.7%
B*3524 (25.5%)21/38/16(10) 41.6%58.4%39.0%
B*5119 (20.2%)14/55/14(10) 52%57.0%74.1%
C*0431 (32.9%)26/59/22(13) 41.9%55.0%46.4%
C*0747 (50%)39/815/32(22) 46.0%61.4%53.1%
DRB1*0324 (25.5%)17/78/16(10) 41.6%62.9%52.6%
DRB1*1143 (45.7%)37/616/27(17) 38.8%59.1%58.7%
  • Patients expressing HLA-B*35 showed severe and frequent immune-related adverse events (irAEs) and the worse 2-year survival rate.

  • Num, numerosity of the patients in each group.